The Zetia controversy and New Year's resolutions will spark new emphasis on treating lipids
The Zetia controversy and New Year's resolutions will spark new emphasis on treating lipids...especially when combo therapy is needed.
We know statins are first-line for lowering LDL and cardiac risk.
But they don't always get patients to their lipid goals. And experts differ about what to do when a statin isn't enough.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote